您現在的位置 :

醫療團隊

專業的醫護人員，提供最佳的醫療服務

醫師介紹

  •

紀廣明醫師

一般內科學、一般消化系統疾病診治、病毒性肝炎診治、肝硬化肝衰竭診治、肝癌藥物治療、診斷性超音波、介入性超音波診治、肝腫瘤消融治療
  • 國語,英語,閩南語,客語
  • 副教授
醫師網路掛號
直接點選進入醫師網路掛號畫面
醫師資歷
  • 現職
    • 高雄長庚紀念醫院 胃腸肝膽科系副教授級主治醫師
    • 長庚大學 醫學系兼任副教授
    • 高雄市肝病防治協會 第3屆總幹事
    • 台灣腫瘤消融醫學會 第7屆理事
  • 學歷
    • 國立陽明大學醫學系學士
    • 長庚大學臨床醫學研究所博士班(就讀中)
    • 日本東京順天堂大學短期進修---射頻消融燒灼術 (2017年7月)
  • 經歷
    • 高雄長庚紀念醫院 內科部住院醫師
    • 高雄長庚紀念醫院 胃腸肝膽科系研究員
    • 鳳山醫院委託高雄長庚醫院經營 胃腸肝膽科主治醫師
    • 高雄市肝病防治協會 第1、2屆理事
    • 台灣腫瘤消融醫學會 第4、5、6屆理事
    • 中華民國醫用超音波學會 第16屆理事、第17屆常務理事
    • 高雄長庚紀念醫院 胃腸肝膽科系副系主任(1060701~1090630)
    • 中華民國醫用超音波學會 第18屆監事
  • 學會與認證
    • 台灣內科醫學會內科專科醫師及指導醫師
    • 台灣消化系醫學會消化系內科專科醫師及指導醫師
    • 台灣消化系內視鏡醫學會消化系內視鏡專科醫師
    • 中華民國醫用超音波學會超音波專業醫師
    • 台灣肝癌醫學會專科醫師
    • 台灣腫瘤消融學會認證肝腫瘤消融手術醫師
    • 台灣醫學教育學會一般醫學師資
  • 論文及期刊發表
    • Kuo YH, Huang TH, Yen YH, Lu SN, Wang JH, Hung CH, Chen CH, Tsai MC, Kee KM*. Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation. Cancers. 2023 June 12;15(12):3156. (SCI)
      列線圖預測早期肝癌經射頻消融後的長期存活率
    • Kee KM, Chen CH, Hu JT, Huang YH, Wang TE, Chau GY, Chen KH, Chen YL, Lin CC, Hung CF, Huang SF, Liu TW, Ku HY, Huang BS, Wang YP, Tseng HP, Chiang CJ, Lu SN*. Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019. Viruses. 2022 Dec 31;15(1):126. (SCI)
      臺灣2011年至2019年肝細胞癌臨床特徵及存活率的年代趨勢
    • Kee KM, Chen WM, Hsu NT, Wang JH, Chao WH, Lin YC, Lu SN*. Community-based screening by Anti-HCV reflex HCV Ag test and accessible post-screening care toward elimination of hepatitis C in two hyperendemic townships. J Formos Med Assoc. 2022 Sep;121(9):1850-1856. (SCI)
      在兩個高盛行城鎮用C肝抗體篩檢接續C肝抗原檢測做社區篩檢和篩檢後可近性照顧以根除C型肝炎
    • Chen HY, Lu SN, Hung CH, Wang JH, Chen CH, Yen YH, Kuo YH, Kee KM*. Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation. PLoS One. 2020 Nov 10;15(11):e0242113. (SCI)
      預測經射頻燒灼術後復發小型肝癌病患之預後
    • Chen CT, Huang WC, Wang JH, Lee CM, Hung CH, Tsai LS, Chen SC, Lin SC, Lu SN, Kee KM*. Endemic hepatitis B and C virus areas are associated with lower prevalence of hyperlipidemia: Ecological and cross-sectional studies. Advances in Digestive Medicine. 2017 June. 4(2):54–60. 台灣消化醫學雜誌

      【Advances in Digestive Medicine (AIDM) 106年度優秀論文獎第一名】
    • Kee KM, Lu SN*. Diagnostic efficacy of ultrasound in hepatocellular carcinoma diagnosis. Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):277-279. (Editorial)

    • Kee KM, Wang JH, Wang CC, Cheng YF, Lu SN*. Hepatocellular Carcinoma associated with Extra-hepatic Primary Malignancy: its Secular change, Clinical Manifestations and Survival. Sci Rep. 2016 Jul 22;6:30156. (SCI)

    • Kee KM, Hung CH, Wang JH, Lu SN*. Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib. OncoTargets and Therapy. 2014 May;7:829-834. (SCI)

    • Kee KM, Wang JH, Lin CY, Wang CC, Cheng YF, Lu SN*. Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center. Dig Dis Sci. 2013 Sep;58(9):2721-8. (SCI)

    • Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Lu SN*. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response. Dig Dis Sci. 2013 Feb;58(2):556-61. (SCI)

    • Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Chang KC, Tseng PL, Yen YH, Lin CY, Lu SN*. Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study. J Gastroenterol Hepatol. 2012 Jun;27(6):1106-11. (SCI)

    • Kee KM, Lu SN*. Hospital- and community-based screenings for hepatocellular carcinoma in Taiwan. Oncology. 2011;81 Suppl 1:36-40. (SCI)

    • Kee KM, Hung CM, Wang JH, Hung CH, Chen PF, Lin KS, Lu SN*. Low accuracy of the national reporting system of acute hepatitis C infection in Taiwan, 1995-2004. J Gastroenterol Hepatol. 2010 Jul;25(7):1289-94. (SCI)

    • Lin CY, Kee KM(co-first), Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lu SN*. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009 Jan;29(1):74-81. (SCI)

    • Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lin CY, Lu SN*. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 2007 Jun 15;120(12):2650-5. (SCI)

    • Kee KM, Lee CM, Wang JH, Tung HD, Changchien CS, Lu SN*, Wang PW. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):319-26. (SCI)

    • Kee KM, Wang JH*, Lee CM, Changchien CS, Eng HL. Chronic hepatitis C virus infection associated with dermatomyositis and hepatocellular carcinoma. Chang Gung Med J. 2004 Nov;27(11):834-9. Review.